NASDAQ:VRAY - Viewray Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Viewray Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.02 -0.06 (-1.47 %) (As of 12/5/2019 04:00 PM ET) Add Compare Today's Range$3.98Now: $4.02▼$4.0750-Day Range$2.39MA: $2.88▼$4.4752-Week Range$2.12Now: $4.02▼$9.76Volume4.44 million shsAverage Volume1.72 million shsMarket Capitalization$399.61 millionP/E RatioN/ADividend YieldN/ABeta1.09 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRAY Previous Symbol CUSIPN/A CIK1597313 Webhttp://www.viewray.com/ Phone440-703-3210Debt Debt-to-Equity Ratio0.62 Current Ratio3.70 Quick Ratio2.58Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$80.96 million Price / Sales4.94 Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book2.30Profitability EPS (Most Recent Fiscal Year)($0.98) Net Income$-76,400,000.00 Net Margins-110.61% Return on Equity-75.41% Return on Assets-37.32%Miscellaneous EmployeesN/A Outstanding Shares99,406,000Market Cap$399.61 million Next Earnings Date3/12/2020 (Estimated) OptionableOptionable Receive VRAY News and Ratings via Email Sign-up to receive the latest news and ratings for VRAY and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VRAY Rates by TradingView Viewray (NASDAQ:VRAY) Frequently Asked Questions What is Viewray's stock symbol? Viewray trades on the NASDAQ under the ticker symbol "VRAY." How were Viewray's earnings last quarter? Viewray Inc (NASDAQ:VRAY) released its earnings results on Tuesday, November, 12th. The company reported ($0.21) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.06. The firm earned $20.90 million during the quarter, compared to the consensus estimate of $20.66 million. Viewray had a negative net margin of 110.61% and a negative return on equity of 75.41%. The company's revenue was up 18.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.39) EPS. View Viewray's Earnings History. When is Viewray's next earnings date? Viewray is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Viewray. What guidance has Viewray issued on next quarter's earnings? Viewray updated its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$80-95 million, compared to the consensus revenue estimate of $$89.28 million. What price target have analysts set for VRAY? 9 analysts have issued 1-year price objectives for Viewray's stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate Viewray's stock price to reach $6.44 in the next year. This suggests a possible upside of 60.3% from the stock's current price. View Analyst Price Targets for Viewray. What is the consensus analysts' recommendation for Viewray? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viewray. What are Wall Street analysts saying about Viewray stock? Here are some recent quotes from research analysts about Viewray stock: 1. According to Zacks Investment Research, "ViewRay Inc. is a medical device company. The company develops advanced radiation therapy technology for the treatment of cancer. MRIdian system provides continuous soft-tissue imaging during treatment. ViewRay Inc. is headquartered in Oakwood Village, Ohio. " (11/16/2019) 2. Northland Securities analysts commented, "We remain confident in our analysis of the clinical benefits of MRgRT, and this study is another data point towards long-term validation." (8/19/2019) 3. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $13 PT on VRAY. 1Q revenue of $20.3MM (-23%) was essentially in line with FactSet consensus of $20.4MM. We think the order beat is a better measure of the momentum of the business. VRAY received orders for seven MRIdians, two more than we were expecting for the second straight quarter. We think the order momentum is a direct result of the strategy that the new management team has implemented since taking over in July 2018. The finishing touches of management’s strategy are still coming together, but we think VRAY is positioned to capitalize on what we expect to be meaningful shift to adaptive therapy and MR linacs." (5/2/2019) Has Viewray been receiving favorable news coverage? News headlines about VRAY stock have been trending somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Viewray earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Viewray. Who are some of Viewray's key competitors? Some companies that are related to Viewray include Natus Medical (NTUS), AxoGen (AXGN), Cutera (CUTR), TransMedics Group (TMDX), Zynex (ZYXI), BioLife Solutions (BLFS), Stereotaxis (STXS), Semler Scientific (SMLR), Edap Tms (EDAP), BioSig Technologies (BSGM), Rockwell Medical (RMTI), Fonar (FONR), Second Sight Medical Products (EYES), Soleno Therapeutics (SLNO) and electroCore (ECOR). What other stocks do shareholders of Viewray own? Based on aggregate information from My MarketBeat watchlists, some companies that other Viewray investors own include Alibaba Group (BABA), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Sarepta Therapeutics (SRPT), Square (SQ), Advanced Micro Devices (AMD), Amarin (AMRN), Amicus Therapeutics (FOLD), Iovance Biotherapeutics (IOVA) and Pieris Pharmaceuticals (PIRS). When did Viewray IPO? (VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers. Who are Viewray's major shareholders? Viewray's stock is owned by many different of retail and institutional investors. Top institutional investors include Millennium Management LLC (1.56%), State Street Corp (1.37%), Rhenman & Partners Asset Management AB (0.65%), Kahn Brothers Group Inc. DE (0.35%), Essex Investment Management Co. LLC (0.15%) and Russell Investments Group Ltd. (0.13%). Company insiders that own Viewray stock include Fmr Llc, International Ltd Fosun, James F Dempsey, Orbimed Advisors Llc, Scott William Drake and Shahriar Matin. View Institutional Ownership Trends for Viewray. Which institutional investors are selling Viewray stock? VRAY stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Rhenman & Partners Asset Management AB, Essex Investment Management Co. LLC, Perkins Capital Management Inc., Pennsylvania Trust Co, Stephens Inc. AR and Squarepoint Ops LLC. View Insider Buying and Selling for Viewray. Which institutional investors are buying Viewray stock? VRAY stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Kahn Brothers Group Inc. DE, Investor AB, Parallel Advisors LLC, Virtu Financial LLC, Raymond James Trust N.A., Allworth Financial LP and Russell Investments Group Ltd.. Company insiders that have bought Viewray stock in the last two years include International Ltd Fosun, Scott William Drake and Shahriar Matin. View Insider Buying and Selling for Viewray. How do I buy shares of Viewray? Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Viewray's stock price today? One share of VRAY stock can currently be purchased for approximately $4.02. How big of a company is Viewray? Viewray has a market capitalization of $399.61 million and generates $80.96 million in revenue each year. The company earns $-76,400,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. View Additional Information About Viewray. What is Viewray's official website? The official website for Viewray is http://www.viewray.com/. How can I contact Viewray? Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected] MarketBeat Community Rating for Viewray (NASDAQ VRAY)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 248 (Vote Outperform)Underperform Votes: 181 (Vote Underperform)Total Votes: 429MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote "Outperform" if you believe VRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/5/2019 by MarketBeat.com StaffFeatured Article: What is the CAC 40 Index?
